EP3725811A3 - Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen - Google Patents

Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen Download PDF

Info

Publication number
EP3725811A3
EP3725811A3 EP19215429.2A EP19215429A EP3725811A3 EP 3725811 A3 EP3725811 A3 EP 3725811A3 EP 19215429 A EP19215429 A EP 19215429A EP 3725811 A3 EP3725811 A3 EP 3725811A3
Authority
EP
European Patent Office
Prior art keywords
compositions
complement activation
dependent complement
inhibiting masp
masp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19215429.2A
Other languages
English (en)
French (fr)
Other versions
EP3725811A2 (de
Inventor
Thomas Dudler
Wayne R. Gombotz
James Brian Parent
Clark E. Tedford
Anita Kavlie
Urs Beat Hagemann
Herald Reiersen
Sergej Kiprijanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47090380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3725811(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Publication of EP3725811A2 publication Critical patent/EP3725811A2/de
Publication of EP3725811A3 publication Critical patent/EP3725811A3/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP19215429.2A 2011-05-04 2012-05-04 Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen Pending EP3725811A3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161482567P 2011-05-04 2011-05-04
EP12779347.9A EP2704743B1 (de) 2011-05-04 2012-05-04 Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen
PCT/US2012/036509 WO2012151481A1 (en) 2011-05-04 2012-05-04 Compositions for inhibiting masp-2 dependent complement acitivation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP12779347.9A Division EP2704743B1 (de) 2011-05-04 2012-05-04 Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen
EP12779347.9A Division-Into EP2704743B1 (de) 2011-05-04 2012-05-04 Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen

Publications (2)

Publication Number Publication Date
EP3725811A2 EP3725811A2 (de) 2020-10-21
EP3725811A3 true EP3725811A3 (de) 2021-01-27

Family

ID=47090380

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19215429.2A Pending EP3725811A3 (de) 2011-05-04 2012-05-04 Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen
EP12779347.9A Active EP2704743B1 (de) 2011-05-04 2012-05-04 Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP12779347.9A Active EP2704743B1 (de) 2011-05-04 2012-05-04 Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen

Country Status (25)

Country Link
US (6) US9011860B2 (de)
EP (2) EP3725811A3 (de)
JP (5) JP5891298B2 (de)
KR (3) KR101882830B1 (de)
CN (2) CN103687620B (de)
AU (1) AU2012250627B2 (de)
BR (1) BR112013028429B1 (de)
CA (3) CA2832871C (de)
CL (1) CL2013003140A1 (de)
CY (1) CY1123212T1 (de)
DK (1) DK2704743T3 (de)
ES (1) ES2795667T3 (de)
HR (1) HRP20200887T1 (de)
HU (1) HUE049154T2 (de)
IL (4) IL229208B (de)
LT (1) LT2704743T (de)
ME (1) ME03755B (de)
MX (3) MX347691B (de)
PL (1) PL2704743T3 (de)
PT (1) PT2704743T (de)
RS (1) RS60541B1 (de)
RU (3) RU2636038C2 (de)
SI (1) SI2704743T1 (de)
WO (1) WO2012151481A1 (de)
ZA (1) ZA201308943B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
EP3521311A1 (de) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Zur wiederholten bindung an zwei oder mehr antigenmoleküle fähiges, antigenbindendes molekül
CA2819356C (en) 2010-11-30 2023-01-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
NZ709997A (en) 2011-04-08 2016-03-31 Univ Leicester Methods for treating conditions associated with masp-2 dependent complement activation
ME03755B (de) * 2011-05-04 2021-04-20 Omeros Corp Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
EP2912065A4 (de) 2012-10-25 2016-10-19 True North Therapeutics Inc Anti-komplement-c1s-antikörper und verwendungen davon
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
WO2014144542A2 (en) * 2013-03-15 2014-09-18 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
EP2982689B1 (de) 2013-04-02 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Varianten der fc-region
ES2829913T3 (es) * 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EA201791754A1 (ru) 2015-02-05 2019-01-31 Чугаи Сейяку Кабусики Кайся АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
GEP20247583B (en) 2015-11-09 2024-01-10 Univ Leicester Methods for treating condi tions associated with masp-2 dependent complement activation
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
AU2017205453B2 (en) * 2016-01-05 2020-03-12 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
US10870708B2 (en) * 2016-03-31 2020-12-22 University Of Leicester Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
JP2021518343A (ja) 2018-03-15 2021-08-02 中外製薬株式会社 ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
JP2021525728A (ja) * 2018-05-29 2021-09-27 オメロス コーポレーション Ｍａｓｐ−２阻害剤および使用方法
CA3119655A1 (en) * 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
EP4069238A1 (de) 2019-12-04 2022-10-12 Omeros Corporation Masp-2-hemmer und verfahren zur verwendung
CA3159159A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
IL293551A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
AU2020398241A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
TW202319069A (zh) * 2020-03-06 2023-05-16 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN114634575A (zh) * 2020-12-16 2022-06-17 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
JP2024509702A (ja) * 2021-02-05 2024-03-05 オメロス コーポレーション 急性ｃｏｖｉｄ－１９および急性後ｃｏｖｉｄ－１９を発症するリスクを評価するためのバイオマーカー
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
TW202305010A (zh) 2021-04-25 2023-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
CN116615544A (zh) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
TW202334242A (zh) * 2021-12-10 2023-09-01 美商歐米諾斯公司 結合ｍａｓｐ－２的絲氨酸蛋白酶結構域的治療性抗體及其用途
CN116284412A (zh) * 2021-12-21 2023-06-23 沈阳三生制药有限责任公司 一种抗masp-2抗体及其制备方法与用途
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106384A1 (en) * 2003-05-12 2004-12-09 Natimmune A/S Antibodies to masp-2
WO2005123128A2 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
EP3366307A1 (de) * 2012-04-06 2018-08-29 Omeros Corporation Zusammensetzungen und verfahren zur hemmung von masp-1 und/oder masp-3 zur behandlung von paroxysmaler nächtlicher hämoglobinurie

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
EP1140171A4 (de) 1998-12-15 2002-03-13 Brigham & Womens Hospital Methoden und produkte zur regulation der, mit dem lectin-komplementsystem assoziierten, komplementaktivierung
ATE399025T1 (de) 1999-07-21 2008-07-15 Omeros Corp Spüllösungen und verfahren zur schmerzhemmung, entzündungshemmung und hemmung des knorpelabbaus
US20010051754A1 (en) 1999-08-03 2001-12-13 Daria N. Lissy Plural stage toluene disproportionation process minimizing ethylbenzene
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
NZ523900A (en) 2000-07-13 2004-02-27 Jens Christian Jensenius Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections
ATE364632T1 (de) 2001-10-05 2007-07-15 Affimed Therapeutics Ag Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation
US7435871B2 (en) * 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
JP4723244B2 (ja) 2002-07-19 2011-07-13 オメロス コーポレイション 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料
EP1598419A1 (de) * 2003-02-28 2005-11-23 Mitsubishi Pharma Corporation Monoklonaler antikörper, dafür codierendes gen, hybridom, medizinische zusammensetzung und diagnostikum
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2344536A1 (de) 2008-09-19 2011-07-20 MedImmune, LLC Gegen dll4 gerichtete antikörper und anwendungen davon
US9403904B2 (en) * 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
CA2971474C (en) * 2009-10-16 2022-11-22 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
ME03755B (de) * 2011-05-04 2021-04-20 Omeros Corp Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106384A1 (en) * 2003-05-12 2004-12-09 Natimmune A/S Antibodies to masp-2
WO2005123128A2 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
EP3366307A1 (de) * 2012-04-06 2018-08-29 Omeros Corporation Zusammensetzungen und verfahren zur hemmung von masp-1 und/oder masp-3 zur behandlung von paroxysmaler nächtlicher hämoglobinurie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LONBERG N ET AL: "ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE COMPRISING FOUR DISTINCT GENETIC MODIFICATIONS", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 368, no. 6474, 28 April 1994 (1994-04-28), pages 856 - 859, XP000941636, ISSN: 0028-0836, DOI: 10.1038/368856A0 *
WILHELM J SCHWAEBLE ET AL: "Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 18, 3 May 2011 (2011-05-03), pages 7523 - 7528, XP002658286, ISSN: 0027-8424, [retrieved on 20110418], DOI: 10.1073/PNAS.1101748108 *
WINTER G ET AL: "MAKING ANTIBODIES BY PHAGE DISPLAY TECHNOLOGY", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, vol. 12, 1 January 1994 (1994-01-01), pages 433 - 455, XP000564245, ISSN: 0732-0582, DOI: 10.1146/ANNUREV.IY.12.040194.002245 *

Also Published As

Publication number Publication date
KR101641057B1 (ko) 2016-07-20
CA3025762C (en) 2021-11-09
JP2018123148A (ja) 2018-08-09
US9475885B2 (en) 2016-10-25
BR112013028429B1 (pt) 2022-11-08
US20170088632A1 (en) 2017-03-30
KR101882830B1 (ko) 2018-07-31
SI2704743T1 (sl) 2020-08-31
US10683367B2 (en) 2020-06-16
CA3131223C (en) 2024-01-30
US10047165B2 (en) 2018-08-14
KR20140006096A (ko) 2014-01-15
PL2704743T3 (pl) 2020-08-24
JP2015227380A (ja) 2015-12-17
RU2725958C2 (ru) 2020-07-07
LT2704743T (lt) 2020-09-10
KR20160087917A (ko) 2016-07-22
BR112013028429A2 (pt) 2020-07-21
NZ617487A (en) 2016-03-31
RU2020120539A (ru) 2021-12-23
IL229208B (en) 2021-03-25
PT2704743T (pt) 2020-06-17
RU2636038C2 (ru) 2017-11-17
DK2704743T3 (en) 2020-05-25
US20160002349A1 (en) 2016-01-07
EP2704743A4 (de) 2014-11-05
JP2020097630A (ja) 2020-06-25
ES2795667T3 (es) 2020-11-24
KR20180086298A (ko) 2018-07-30
EP2704743A1 (de) 2014-03-12
CY1123212T1 (el) 2021-10-29
HRP20200887T1 (hr) 2020-09-04
JP6352226B2 (ja) 2018-07-04
CN107011443A (zh) 2017-08-04
US20210054099A1 (en) 2021-02-25
MX2018014714A (es) 2021-11-16
KR102024016B1 (ko) 2019-11-04
JP2014515922A (ja) 2014-07-07
RU2013153527A (ru) 2015-06-10
NZ715226A (en) 2017-07-28
JP2022172275A (ja) 2022-11-15
EP3725811A2 (de) 2020-10-21
EP2704743B1 (de) 2020-03-11
US20240092938A1 (en) 2024-03-21
HUE049154T2 (hu) 2020-09-28
US20190119402A1 (en) 2019-04-25
MX347691B (es) 2017-05-09
CA3025762A1 (en) 2012-11-08
CN103687620B (zh) 2017-10-13
US11613589B2 (en) 2023-03-28
MX2013012862A (es) 2013-12-02
JP5891298B2 (ja) 2016-03-22
CN107011443B (zh) 2021-04-30
CA3131223A1 (en) 2012-11-08
RU2017137872A (ru) 2019-04-30
CL2013003140A1 (es) 2014-05-23
AU2012250627A1 (en) 2013-03-21
NZ733310A (en) 2021-12-24
CA2832871A1 (en) 2012-11-08
RS60541B1 (sr) 2020-08-31
JP6669800B2 (ja) 2020-03-18
CA2832871C (en) 2019-01-15
ZA201308943B (en) 2015-05-27
ME03755B (de) 2021-04-20
MX361175B (es) 2018-11-29
IL266756B (en) 2021-08-31
IL266756A (en) 2019-07-31
US9011860B2 (en) 2015-04-21
IL285522A (en) 2021-09-30
AU2012250627B2 (en) 2016-01-07
CN103687620A (zh) 2014-03-26
RU2017137872A3 (de) 2019-04-30
WO2012151481A1 (en) 2012-11-08
US20120282263A1 (en) 2012-11-08
IL229208A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
EP3725811A3 (de) Zusammensetzungen zur hemmung masp-2-abhängiger komplementaktivierungen
EP3679141A4 (de) Verfahren und zusammensetzungen zur hemmung der ldha-expression
EP3838921A3 (de) Anti-tau-antikörper
IN2015DN01197A (de)
IN2015DN01161A (de)
IN2015DN00127A (de)
EP2877159B8 (de) Efflux-inhibitorzusammensetzungen und behandlungsverfahren damit
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
TN2013000310A1 (en) Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections
WO2012142498A3 (en) Mif inhibitors and their uses
IN2014DN10576A (de)
IN2014DN08721A (de)
IN2013MN01582A (de)
MX2023010206A (es) Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
PH12014501032A1 (en) 2-thiopyrimidinones
EP4023243A3 (de) Zusammensetzungen und verfahren zur behandlung von zöliakie/sprue
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
IN2014DN00254A (de)
MY172557A (en) Compositions for the treatment of hypertension and/or fibrosis
EP2576536A4 (de) Hämatopoetische prostaglandin-d2-synthase-inhibitoren
AU2012270029A8 (en) Compositions and methods for modulating a kinase
WO2014093988A3 (en) Methods and compositions for inhibiting cnksr1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2704743

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KAVLIE, ANITA

Inventor name: KIPRIJANOV, SERGEJ

Inventor name: REIERSEN, HERALD

Inventor name: PARENT, JAMES BRIAN

Inventor name: TEDFORD, CLARK E.

Inventor name: GOMBOTZ, WAYNE R.

Inventor name: HAGEMANN, URS BEAT

Inventor name: DUDLER, THOMAS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TEDFORD, CLARK E.

Inventor name: KAVLIE, ANITA

Inventor name: PARENT, JAMES BRIAN

Inventor name: DUDLER, THOMAS

Inventor name: HAGEMANN, URS BEAT

Inventor name: KIPRIJANOV, SERGEJ

Inventor name: REIERSEN, HERALD

Inventor name: GOMBOTZ, WAYNE R.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20201218BHEP

Ipc: C07K 16/40 20060101AFI20201218BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039718

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210722

RAX Requested extension states of the european patent have changed

Extension state: BA

Payment date: 20210722

Extension state: ME

Payment date: 20210722

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231026